Research programme: bispecific protein therapeutics - Bitterroot Bio/Biotheus
Latest Information Update: 26 Mar 2024
At a glance
- Originator Biotheus; Bitterroot Bio
- Class Cardiovascular therapies; Vascular disorder therapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Atherosclerosis; Cardiovascular disorders
Most Recent Events
- 26 Feb 2024 Early research in Atherosclerosis in China (unspecified route), prior to February 2024
- 26 Feb 2024 Early research in Cardiovascular disorders in China (unspecified route), prior to February 2024